19677-69-1

Basic information

• Product Name: (4-ethoxypyridin-2-yl)Methanol
• Synonyms: (4-ethoxypyridin-2-yl)Methanol
• CAS NO: 19677-69-1
• Molecular Formula: C₈H₁₁NO₂
• Molecular Weight: 153.17844
• Mol File: 19677-69-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (4-ethoxypyridin-2-yl)Methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (4-ethoxypyridin-2-yl)Methanol(19677-69-1)
• EPA Substance Registry System: (4-ethoxypyridin-2-yl)Methanol(19677-69-1)

Safety Data

• Hazardous Substances Data: 19677-69-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(4-ethoxypyridin-2-yl)Methanol is used as a chemical intermediate for the synthesis of pharmaceutical compounds, leveraging its reactivity and structural features to create a variety of medicinal agents.
Used in Agrochemical Industry:
EPM is utilized as a building block in the development of agrochemicals, contributing to the creation of products designed to enhance crop protection and yield.
Used in Organic Synthesis:
(4-ethoxypyridin-2-yl)Methanol is used as a reagent in organic synthesis, particularly for the preparation of heterocyclic compounds, which are integral in the formation of complex organic molecules.
Used in Biological Research:
EPM is employed as a subject of study in biological research, exploring its potential anti-inflammatory and anti-cancer properties for possible therapeutic applications.

Upstream product

• 98197-88-7 4-nitro-2-(hydroxymethyl)pyridine 
• 64-17-5 ethanol 
• 141-52-6 sodium ethanolate 
• 109-06-8 α-picoline 
• 5470-66-6 2-methyl-4-nitropyridine N-oxide 
• 931-19-1 2-methylpyridine N-oxide 
• 14474-56-7 4-ethoxypyridine-N-oxide 
• 77-78-1 dimethyl sulfate 
• 26883-31-8 4-ethoxy-2-methyl-pyridine-1-oxide 

Downstream Products

• 16665-43-3 4-ethoxypicolinaldehyde 
• 159996-13-1 2-(chloromethyl)-4-ethoxypyridine 

Relevant articles and documents

ANALOGS OF 2-PRALIDOXIME AS ANTIDOTES AGAINST ORGANOPHOSPHORUS NERVE AGENTS

Provided herein are compounds useful in treating exposure to an organophosphorus compound, such as a nerve agent, pesticide, or, generally, an acetylcholinesterase inhibitor, such as sarin. Compositions, e.g. pharmaceutical compositions or dosage forms, comprising the compounds also are provided herein. Methods of treating a patient exposed to a nerve agent, pesticide, or, generally, an acetylcholinesterase inhibitor, e.g., an organophosphorus compound, such as sarin, also are provided.

BENZIMIDAZOLE COMPOUNDS AS AGRICULTURAL CHEMICALS

The present invention relates tobenzimidazole ethers and related compounds which are of use in the field of agriculture as fungicides.

Design and synthesis of N-Aryl isothioureas as a novel class of gastric H+/K+-ATPase inhibitors

To find new H+/K+-ATPase inhibitors for the treatment of peptic ulcer disease, a series of novel N-aryl isothiourea derivatives were synthesized and their structures were identified by 1H NMR and GC-MS. The effects of these compounds on inhibiting gastric acid secretion were evaluated by the guinea pig stomach mucous membrane study with pantoprazole magnesium as a positive control. The results showed that, of the 37 N-aryl isothiourea compounds synthesized, 20 compounds have comparable or stronger gastric acid inhibitory activities than that of pantoprazole magnesium. The quantitative structure-activity relationships (QSARs) of the N-aryl isothiourea compounds were also studied by comparative molecular field analysis (CoMFA) computation, and the model structure that was supposed to give more powerful bioactivities was finally predicted. A series of novel N-aryl isothiourea derivatives were synthesized and evaluated for their effects of inhibiting gastric acid secretion using the guinea pig stomach mucous membrane study with pantoprazole magnesium as a positive control. Compounds 2c, 2e, and 2k have higher bioactivity. The quantitative structure-activity relationships also defined these structural requirements.

Tuning of the properties of transition-metal bispidine complexes by variation of the basicity of the aromatic donor groups

Bispidines (3,7-diazabicyclo[3.3.1]nonanes) as very rigid and highly preorganized ligands find broad application in the field of coordination chemistry, and the redox potentials of their transition-metal complexes are of importance in oxidation reactions by high-valent iron complexes, aziridination catalyzed by copper complexes, and imaging by 64Cu positron emission tomography tracers. Here, we show that the redox potentials and stability constants of the copper(II) complexes of 15 tetradentate bispidines can be varied by substitution of the pyridine rings (variation of the redox potential over ca. 450 mV and of the complex stability over approximately 10 log units). It is also shown that these variations are predictable by the pKa values of the pyridine groups as well as by the Hammett parameters of the substituents, and the density functional theory based energy decomposition analysis also allows one to accurately predict the redox potentials and concomitant complex stability. It is shown that the main contribution emerges from the electrostatic interaction energy, and the partial charges of the pyridine donor groups therefore also correlate with the redox potentials.

BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE

The present invention provides a novel benzazepine derivative represented by formula : wherein, R1 is a 5- or 6-membered aromatic ring, R2 is lower alkyl group, etc., Y is an optionally substituted imino group, ring A and ring B are independently an optionally substituted aromatic ring, W is formula -W1-X2-W2- (W1 and W2 are independently S(O)m1 (m1 is 0, 1 or 2), etc., and X2 is an optionally substituted alkylene groupetc. ), a preparation method and use thereof.

2--1H-thienoimidazoles. A Novel Class of Gastric H+/K+-ATPase Inhibitors

2-thienoimidazoles were synthesized and investigated as potential inhibitors of gastric H+/K+-ATPase.The isomers of the two possible thienoimidazole series were found to be potent inhibitors of gastric acid secretion in vitro and in vivo.Structure-activity relationships indicate that especially lipophilic alkoxy, benzyloxy, and phenoxy substituents with additional electron-demanding properties in the 4-position of the pyridine moiety combined with an unsubstituted thienoimidazole lead to highly active compounds with a favorable chemical stability.Various substitution patterns in the thienoimidazole moiety result in lower biological activity.The heptafluorobutyloxy derivative saviprazole (HOE 731, 5d) was selected for further development and is currently undergoing clinical evaluation.Comprehensive pharmacological studies indicate a pharmacodynamic profile different to omeprazole, the first H+/K+-ATPase blocker introduced on the market.